Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENA-001 Administered as Intravenous (IV) and Intramuscular (IM) Doses

NCT06967259 is registered in ClinicalTrials.gov with Enalare Therapeutics Inc. as lead sponsor.

NCT NCT06967259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06967259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ENA-001 Administered as Intravenous (IV) and Intramuscular (IM) Doses
Lead sponsor
Enalare Therapeutics Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 14, 2025
Completion date
August 12, 2026
Enrollment
62 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory depression